Related Experiment Video

Updated: Aug 27, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

RET/PTC oncoproteins: molecular targets of new drugs

Cinzia Lanzi1, Giuliana Cassinelli, Giuditta Cuccuru

  • 1Department of Experimental Oncology, Preclinical Chemotherapy and Pharmacology Unit, National Cancer Institute, Milan, Italy. lanzicinzia@istitutotumori.mi.it

Tumori
|February 12, 2004
PubMed

Insights

Ret oncoproteins are key targets in thyroid cancer. The inhibitor RPI-1 effectively blocks Ret signaling and inhibits tumor cell growth, supporting its potential as a therapeutic agent for RET-driven thyroid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ret oncoproteins are implicated in thyroid carcinomas, including papillary thyroid carcinomas (PTC) and medullary thyroid carcinomas (MTC).
  • Oncogenic activation of the RET gene, through rearrangement or mutation, leads to deregulated Ret oncoproteins with ligand-independent tyrosine kinase activity.
  • This constitutive activation presents a therapeutic vulnerability for targeted intervention.

Purpose of the Study:

  • To investigate the cellular effects of the arylidene 2-indolinone Ret inhibitor, RPI-1, on a human papillary thyroid carcinoma cell line.
  • To evaluate RPI-1's potential as a therapeutic agent by assessing its impact on Ret/ptc1 signaling and cell growth.

Main Methods:

  • Utilized the human PTC cell line TPC-1, which harbors the RET/PTC1 oncogene.
  • Administered the Ret inhibitor RPI-1 to TPC-1 cells.
  • Assessed the effects of RPI-1 on cell growth and Ret/ptc1-driven signaling pathways.

Main Results:

  • RPI-1 demonstrated significant inhibition of cell growth in TPC-1 cells.
  • The inhibitor effectively interfered with the signaling pathways driven by the Ret/ptc1 oncogene.
  • These findings confirm the biological activity of RPI-1 against Ret oncoproteins.

Conclusions:

  • Ret oncoproteins are validated therapeutic targets in thyroid cancer.
  • RPI-1 exhibits promising preclinical activity, warranting further investigation as a potential drug for thyroid tumors with RET oncogenic alterations.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...